SEC filing – odaterad – tm2619347d1_6k.htm

Fulltext

6-K
1
tm2619347d1_6k.htm
FORM 6-K

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE
ISSUER

PURSUANT TO RULE 13a-16
OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of July 2026

 

(Commission File No. 001-43312)

 

Vicore Pharma Holding
AB

(Translation of registrant’s name into
English)

 

Kornhamnstorg 53

SE-111 27 Stockholm,

Sweden

(Address of registrant’s principal executive
office)

 

Indicate by check mark whether
the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F  x     Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101 (b) (1):  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101 (b) (7):  ¨

 

 

 

 

 

 

Changes to Management

 

On July 6, 2026, Vicore
Pharma Holding AB (the “Company”) issued a press release announcing the appointment of Rob Slack, PhD, FRSB to serve as the
Company’s Chief Scientific Officer. The press release is attached as Exhibit 99.1 and is incorporated by reference herein.

 

Exhibits
 

 
 

99.1
Press
Release, dated July 6, 2026

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 
Vicore Pharma Holding AB

 
 
 

 
By:

/s/ Ahmed Mousa

 
Name:
Ahmed Mousa

 
Title:
Chief Executive Officer

 

Date: July 6, 2026